SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending as its BlueBird 6 satellite successfully unfolded, a significant technical milestone seen by the community as de-risking the technology and validating its path to ubiquitous direct-to-device connectivity. This, alongside FCC approval for US beta testing with major carriers, fuels excitement for commercial rollout.

SSgA Active Trust - SPDR Dow Jones Industrial Average ETF

The SPDR Dow Jones Industrial Average ETF (DIA) is trending as the Dow Jones Industrial Average reaches new all-time highs, with some celebrating a 50,000 milestone while others debate its sustainability amid cautious economic data and shifts in market leadership.

Mattel, Inc. engages in the ownership of children's and family entertainment franchises. It operates through the following segments: North America, International, and American Girl. The North America and International segments focus on marketing and selling toys and consumer products. The American Girl segment includes marketing, retailing, and publishing dedicated to its mission to help girls grow up with confidence and character. The company was founded by Elliot Handler, Ruth Handler, and Harold Matson in 1945 and is headquartered in El Segundo, CA.

Mattel, Inc.

Mattel is experiencing extreme volatility following a significant earnings miss for the holiday quarter and soft guidance, which triggered a dramatic sell-off that has investors debating if the decline is overdone amidst a new $1.5 billion share buyback program and the ongoing shift of consumer preferences toward digital entertainment.

Fermi, Inc. engages in the development of energy infrastructure. It intends to develop an energy and data center development campus to support the needs of to-be-built AI infrastructure. The company was founded by Rick Perry, Toby Neugebauer and Griffin Perry on January 10, 2025 and is headquartered in Amrillo, TX.

Fermi Inc

Fermi LLC

Fermi is trending sharply lower after its first key tenant terminated a $150 million funding agreement for the Project Matador AI data center campus. The community is divided, with many viewing the sell-off as an overreaction and a buying opportunity for a company positioned to meet critical AI power demands, while skeptics point to ongoing lawsuits and zero revenue.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY is a major trending topic as investors eagerly await the week's key jobs report and CPI data, with community discussion sharply divided between those expecting a market rally on potential rate cuts and bears anticipating a significant downturn, amid ongoing observations of overnight futures pumps.

Lyft, Inc. engages in the provision and management of an online social rideshare community platform. It offers access to a network of shared bikes and scooters for shorter rides and first mile and last-mile legs of multimodal trips, information about nearby public transit routes, and Lyft Rentals to offer riders a view of transportation options when planning any trip. The company was founded by Marcus Cohn, John Zimmer, Rajat Suri, Matt van Horn, and Logan Green in 2007 and is headquartered in San Francisco, CA.

Lyft Inc - Ordinary Shares Cls A

Lyft Inc

Lyft is trending after a post-earnings sell-off that the community largely views as an algorithmic overreaction, arguing the company posted a revenue beat when accounting for a one-time adjustment, paired with a significant EPS beat and a new $1 billion share buyback.

Cloudflare, Inc. engages in the provision of cloud-based services to secure websites. It offers various products for performance and reliability, video streaming and delivery, advanced security, insights, Cloudflare for developers, domain registration, and Cloudflare marketplace. It operates through the United States and Rest of the World geographical segments. The company was founded by Matthew Prince, Michelle Zatlyn, and Lee Holloway in July 2009 and is headquartered in San Francisco, CA.

Cloudflare Inc - Ordinary Shares - Class A

Cloudflare Inc

Cloudflare is trending after surpassing revenue expectations and positioning itself as a pivotal infrastructure provider for the "agentic internet" and AI workloads, fueling community discussion about its distinction from typical software companies amidst broader market trends.

HOPPY is a memecoin launched on Ethereum as a tribute to the frog from the famous comic book «The Night Riders», published in 2012 by artist and illustrator Matt Furie, which has gained popularity.   HOPPY appeals to the cryptocurrency community with its no-tax policy and transparent acknowledgment of its lack of utility, maintaining the essence of a pure and simple memecoin.

Hoppy

$HOPPY is trending as the "second frog" in the popular "three frog narrative" alongside $PEPE and $FEFE, fueling community excitement for its potential as a beta play in the meme coin sector. Despite some confusion regarding multiple tokens, its strong community believes in massive upside and accumulating, viewing it as a resilient asset poised for significant growth.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is trending due to recent ultra high-grade drill results from its Tanbreez project, which confirm significant heavy rare earth content and resource expansion. The community is actively discussing the project's strategic importance for Western supply chains, potential undervaluation based on its Preliminary Economic Assessment, and anticipating further government funding or strategic partnerships amid rising global demand for critical minerals.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is trending after its Q4 earnings revealed an EPS beat but a revenue miss, primarily impacted by declining crypto trading. This has polarized the community, with some anticipating further downside due to crypto volatility, while others view it as a buying opportunity, highlighting growth in Gold subscribers and its expanding prediction market business.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Evommune stated that it designed the Phase 2a trial to evaluate the safety and efficacy of an intravenous 5 milligram per kilogram dose of EVO301 over 12 weeks.</li><li>The company said it had 70 patients in the trial, and EVO301 achieved a 33% placebo-adjusted improvement in the Eczema Area and Severity Index at week 12.</li><li>Evommune said EVO301 showed a favorable safety profile with no serious adverse events reported.</li></ul>Evommune Inc. (EVMN) shares nearly doubled in value in Tuesday’s pre-market trade before paring some of the gains to hover 50% higher in the opening trade after the company reported positive results from its atopic dermatitis trial.Evommune stated that its atopic dermatitis treatment, EVO301, met its primary endpoint at week 12 during the&nbsp;mid-stage trial. The company said that EVO301 achieved highly statistically significant outcomes in adult patients with moderate-to-severe atopic dermatitis.Retail sentiment around&nbsp;<a href="https://stocktwits.com/symbol/EVMN">Evommune</a> trended in the ‘neutral’ territory at the time of writing. The EVMN stock was among the top five trending tickers on the platform.<h2 class="st-heading-2">Evommune Details Results Of The Trial</h2>Evommune stated that it designed the Phase 2a trial to evaluate the safety and efficacy of an intravenous 5 milligram per kilogram dose of EVO301 over 12 weeks.“These data support our plans to move EVO301 into a Phase 2b dose-ranging trial where we can optimize the dose and seek to further improve patient outcomes,” said Evommune President and CEO, Luis Peña.The company said it had 70 patients in the trial, and EVO301 achieved a 33% placebo-adjusted improvement in the Eczema Area and Severity Index (EASI) at week 12.Evommune said EVO301 showed a favorable safety profile, with no serious adverse events reported and no treatment-related discontinuations due to adverse events.Dr. Mark G. Lebwohl, Dean for Clinical Therapeutics and Chairman Emeritus of the Department of Dermatology at the Icahn School of Medicine at Mount Sinai, stated that EVO301’s ability to target the interleukin-18 (IL-18) mechanism and demonstrate clinically relevant activity could present patients with “real benefits.”<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>One bullish user stated that there has been “only good news” with the Evommune stock so far.<stembedurl>https://stocktwits.com/swingingg/message/644564885</stembedurl>Another user stated that the IL-18, a known inflammatory pathway which plays a key role in various immune processes, is “working great” for dermatitis.<stembedurl>https://stocktwits.com/JanetBSmellin/message/644548490</stembedurl><a href="https://stocktwits.com/symbol/EVMN">EVMN stock</a> is up 45% year-to-date and 44% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/cryptocurrency/michael-saylor-bitcoin-volatility-bug-as-well-as-feature/cZbUI8AR4Yx">Michael Saylor Calls Bitcoin Volatility Both A Bug And A Feature, Touts It As ‘Digital Capital’: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

This Biotech Stock Nearly Doubled In Value Today Morning – What’s Driving Investor Optimism?

The company said that EVO301 achieved highly statistically significant outcomes in adult patients with moderate-to-severe atopic dermatitis.

Equity

Evommune (NYSE:EVMN) Stock Price Down 5.3% - Time to Sell?

Evommune (NYSE:EVMN) Shares Down 5.3% - Here's What Happened...

Evommune (NYSE:EVMN) Trading 10% Higher - What's Next?

Evommune (NYSE:EVMN) Stock Price Up 10% - Time to Buy...

Evommune (NYSE:EVMN) Now Covered by Oppenheimer

Oppenheimer initiated coverage on Evommune in a research report on Thursday. They set an "outperform" rating and a $42.00 price objective on the stock...

Evommune (NYSE:EVMN) Stock Price Up 7.7% - Still a Buy?

Evommune (NYSE:EVMN) Trading 7.7% Higher - Still a Buy...

Evommune, Inc. (NYSE:EVMN) Given Consensus Recommendation of "Buy" by Analysts

Shares of Evommune, Inc. (NYSE:EVMN - Get Free Report) have been assigned an average recommendation of "Buy" from the ten analysts that are currently covering the firm, Marketbeat Ratings reports...

Evommune (NYSE:EVMN) Trading Down 7.7% - Here's What Happened

Evommune (NYSE:EVMN) Stock Price Down 7.7% - Should You Sell...

Evommune (NYSE:EVMN) Shares Gap Up - What's Next?

Evommune (NYSE:EVMN) Shares Gap Up - Here's Why...

Evommune (NYSE:EVMN) Trading 5.3% Higher - Time to Buy?

Evommune (NYSE:EVMN) Trading Up 5.3% - Here's Why...

Evommune, Inc. (NYSE:EVMN) Given Consensus Rating of "Buy" by Brokerages

Shares of Evommune, Inc. (NYSE:EVMN - Get Free Report) have received an average recommendation of "Buy" from the seven brokerages that are currently covering the stock, MarketBeat reports. One...

Evommune, Inc. is a clinical-stage biotechnology company. It engages in the development of medicines for inflammatory diseases. The company was founded by Luis C. Pena, Eugene Andrew Bauer, and Hans Hofland in 2020 and is headquartered in Palo Alto, CA.

Evommune Inc.

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $SHOP earnings on Wednesday?

Stocktwits

Shopify Inc

Stocktwits Polls

Evommune Inc

The stock is surging after positive Phase 2a clinical trial results for its eczema drug, EVO301, met primary endpoints with robust efficacy.

Analysts are rapidly raising price targets, with some firms like H.C. Wainwright increasing to $65 and Evercore ISI to $55, driven by the strong clinical data.

Traders are keenly watching for a potential short squeeze as the price rises significantly, trapping bearish bets and fueling further upward movement.

High volatility and wide price ranges throughout the day are creating ample scalping and day trading opportunities for short-term momentum traders.

EVMN's sharp rise is contributing to a noticeable buzz across the biotech sector, drawing attention to other companies with clinical trial news.

Current Price	$29.03
Prev Close	$16.99
Open	$29.52
Dividend Yield	N/A
50-Day Moving Average	$18.62
Beta	0.00
Avg. Volume	366,940.50
PE Ratio	N/A

52-Week High	$24.03
52-Week Low	$13.89
Market Capitalization	$535.59M
EPS (Annual)	-$2.27
Price to Book	-2.92
Revenue Per Employee	$170,731.71

EVMN
Evommune Inc

Feed

News

Sentiment

Fundamentals

Info

Latest EVMN News

EVMNEvommune Inc